Sfoglia per AUTORE
ADAMO V
Collezione AO Cuneo

  

Items : 9

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. in Scientific reports / Sci Rep. 2021 Jul 2;11(1):13770. doi: 10.1038/s41598-021-92774-z.

2021
AO Cuneo

Vici P; Ciliberto G; Sanguineti G; Di Leo A; De Maria R; Daralioti T; Sperduti I; Perracchio L; di Benedetto A; Del Medico P; Roselli M; Vaccaro A; Garufi C; Cazzaniga M; Lorusso V; Russo A; Pistelli M; Giotta F; Meattini I; Garrone O; Paris I; Sarobba G; Veltri E; Corsi D; D'Ostilio N; Grassadonia A; Valerio MR; Mirabelli R; Fabbri MA; et alii...

Prospective, randomised, multicentre, open-label trial, designed to evaluate the best timing of closure of the temporary ileostomy (early versus late) in patients who underwent rectal cancer resection and with indication for adjuvant chemotherapy: the STOMAD (STOMa closure before or after ADjuvant therapy) randomised controlled trial. in BMJ open / BMJ Open. 2021 Feb 19;11(2):e044692. doi: 10.1136/bmjopen-2020-044692.

2021
ASL Torino 5
ASL Torino 4
ASL Asti
ASL Vercelli
ASL Torino 3
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AO Cuneo
ASL Città di Torino
ASL Biella
AOU Città della Salute di Torino
ASL VCO
ASL Cuneo 2
ASL Cuneo 1
ASL Alessandria
AOU Novara

Trapani R; Mellano A; Gibin E; Bellomo P; Mineccia M; De Rosa C; Battafarano F; Serventi A; Giaminardi E; Mazza L; Bellora P; Colli F; Cravero F; Piscioneri D; Rimonda R; Adamo V; Brunetti M; Panier Suffat L; Potente F; Carrera M; Saccona F; Ponte E; Mistrangelo M; Santarelli M; Tomaselli F; Reddavid R; Birolo S; Calabrò M; Pipitone N; et alii...

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. in Journal of cellular physiology / J Cell Physiol. 2020 Nov;235(11):7900-7910. doi: 10.1002/jcp.29445. Epub 2020 Jan 15.

2020
AO Cuneo

Vici P; Giordano A; Barba M; Mazzotta M; Sperduti I; Ciliberto G; Villa A; Risi E; De Maria R; Del Medico P; Generali D; Meattini I; Livi L; Garrone O; Baldini E; Zamagni C; Pistelli M; Cannita K; Valerio MR; Berardi R; Russo A; Ricciardi G; Adamo V; Ficorella C; Roselli M; Lorusso V; Landucci E; Paris I; Giotta F; et alii...

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. in Journal of experimental & clinical cancer research : CR / J Exp Clin Cancer Res. 2020 Dec 10;39(1):279. doi: 10.1186/s13046-020-01797-3.

2020
AO Cuneo

Roselli M; Del Medico P; Cazzaniga M; Garufi C; Sarobba G; Giotta F; Paris I; Garrone O; Veltri E; Corsi D; D'Ostilio N; Fabbri MA; Russo A; Mirabelli R; Valerio MR; Marchetti P; Tomao S; Marinelli D; Mazzotta M; Barchiesi G; Zamagni C; Tonini G; Adamo V; Michelotti A; Moscetti L; Bria E; Cassano A; La Verde N; Generali D; et alii...

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. in International journal of cancer / Int J Cancer. 2020 Apr 1;146(7):1917-1929. doi: 10.1002/ijc.32583. Epub 2019 Aug 7.

2020
AO Cuneo

Vici P; Di Leo A; Barba M; Villa A; Ciliberto G; Sperduti I; De Maria R; Risi E; Generali D; De Tursi M; Sarobba G; Del Medico P; Meattini I; Desideri I; Livi L; Baldini E; Di Cocco B; Foglietta J; Greco F; Zamagni C; Garrone O; D'Ostilio N; Sini V; Cannita K; Adamo V; Ricciardi GRR; Fiorio E; Pistelli M; Russo A; et alii...

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. in Oncotarget / Oncotarget. 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176. eCollection 2017 Aug 22.

2017
AO Cuneo

Ciliberto G; Di Cocco B; Marolla P; Sanguineti G; Garrone O; Della Giulia M; Laudadio L; Greco F; Barni S; Lorusso V; Cannita K; Russo A; Adamo V; Giotta F; Tomao S; Ficorella C; Alberti AM; Landucci E; Rossi E; Barba M; Maugeri-Saccà M; Sini V; Mauri M; D'Onofrio L; Scinto AF; Zampa G; Bertolini I; Botticelli A; Piacentini F; et alii...

State-of-the-art and emerging treatment options in the management of head and neck cancer: news from 2013. in Oncology / Oncology. 2014;86(4):212-29. doi: 10.1159/000357712. Epub 2014 May 10.

2014
AO Cuneo

Denaro N; Russi EG; Adamo V; Merlano MC;

The role of antiangiogenic agents in the treatment of head and neck cancer. in Oncology / Oncology. 2012;83(2):108-16. doi: 10.1159/000339542. Epub 2012 Jul 9.

2012
AO Cuneo

Denaro N; Russi EG; Colantonio I; Adamo V; Merlano MC;

The Role of p53 and MDM2 in Head and Neck Cancer. in ISRN otolaryngology / ISRN Otolaryngol. 2011 Dec 7;2011:931813. doi: 10.5402/2011/931813. Print 2011.

2011
AO Cuneo

Denaro N; Lo Nigro C; Natoli G; Russi EG; Adamo V; Merlano MC;